Obsolescence of Pethidine (Meperidine) in Modern Analgesic Practice
WHO Opioid Classification
- The World Health Organization (WHO) classifies pethidine as inappropriate for Level 3 opioid use because safer and more effective alternatives are now available, rendering pethidine effectively obsolete for most clinical indications. 1
Safety Concerns – Neurotoxic Metabolite
- Pethidine is metabolized to normeperidine, a neurotoxic compound with a long half‑life (≈15–30 h) that can accumulate with repeated dosing, increasing the risk of central nervous system excitation (e.g., tremor, myoclonus, seizures). 1
Drug‑Interaction Hazard with MAO Inhibitors
- Concomitant use of pethidine and monoamine‑oxidase inhibitors (MAOIs) can precipitate life‑threatening reactions—including agitation, hemodynamic instability, rigidity, seizures, and death—an interaction not shared by other commonly used opioids such as fentanyl or morphine. 2
Limited Analgesic Efficacy Compared with Alternatives
- Clinical evidence shows that pethidine provides analgesic potency and duration that are comparable to or inferior to morphine, fentanyl, tramadol, and even non‑opioid NSAIDs for postoperative and labor pain, with no advantage for biliary colic or pancreatitis. 3
Remaining Niche Indication – Post‑operative Shivering
- For the treatment of postoperative shivering, pethidine is more effective than other opioid agonists or agonist‑antagonists; however, this narrow benefit does not justify routine formulary inclusion, and shivering should first be addressed by re‑warming measures. 4
Historical Evolution of Opioid Practice
| Period | Key Development | Clinical Impact | |
|---|---|---|---|
| WWII | Introduction of synthetic opioid pethidine | Provided an alternative to morphine during wartime shortages | |
| 1946 | Adoption in the Liverpool balanced‑anaesthesia technique | Integrated pethidine into peri‑operative analgesic regimens | |
| 1962 | Development of fentanyl with superior hemodynamic stability | Shifted preference toward fentanyl for stronger, safer analgesia | |
| Modern era | Preference for ultra‑short‑acting agents (e.g., remifentanil) | Rendered pethidine largely redundant in contemporary practice | [5] |
Guideline Consensus
- Multiple guideline statements (e.g., cancer pain management standards) unequivocally recommend discontinuing pethidine in favor of opioids lacking neurotoxic metabolites and dangerous interaction profiles. 3
Disadvantages of Demerol (Meperidine) for Pain Management
Major Clinical Disadvantages
- Meperidine is contraindicated in patients with renal insufficiency (GFR <30 mL/min/1.73 m²) and end-stage renal disease due to accumulation of active metabolites, as recommended by the Mayo Clinic Proceedings 6, 7, 8
- The medication has serotonergic effects that increase the likelihood of toxicity when combined with other medications that increase serotonergic activity, according to the Mayo Clinic Proceedings and other guidelines 6, 9
Special Population Considerations
- Patients with renal impairment should avoid meperidine due to accumulation of normeperidine, which can cause seizures, as stated by the Mayo Clinic Proceedings and the Journal of Clinical Oncology 6, 7, 8
Superior Alternatives
- For moderate to severe pain, the Journal of Clinical Oncology and the Journal of the National Comprehensive Cancer Network recommend using morphine, hydromorphone, oxycodone, or fentanyl, which provide more reliable analgesia with better safety profiles 8, 10
- For patients with renal impairment, the Journal of Clinical Oncology suggests using fentanyl, sufentanil, or methadone (under experienced supervision) as they have no active metabolites 8
- The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends optimizing pain management strategies away from meperidine due to its poor efficacy, multiple drug interactions, and increased risk of toxicity, as stated in the Mayo Clinic Proceedings 6, 11, 7